# Asunercept for the Treatment of Patients With Moderate to Severe COVID-19 Disease

> **NCT05639192** · PHASE3 · TERMINATED · sponsor: **Apogenix GmbH** · enrollment: 34 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Asunercept
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05639192
- **Lead sponsor:** Apogenix GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-11-03
- **Primary completion:** 2023-08-18
- **Final completion:** 2023-08-18
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** Lack of patients
- **Last updated:** 2023-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05639192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05639192, "Asunercept for the Treatment of Patients With Moderate to Severe COVID-19 Disease". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT05639192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*